Document is current

Svecla, Monika

Moregola, Annalisa

Dalt, Lorenzo Da

Nour, Jasmine

Baragetti, Andrea

Uboldi, Patrizia

Idini, Alessandra

Wuhrer, Manfred

Beretta, Giangiacomo

Falck, David

Bonacina, Fabrizia

Norata, Giuseppe Danilo

Funding for this research was provided by:

EAS Competitive Grant (LDD)

Progetti di Rilevante Interesse Nazionale ((PRIN-PNRR 2022 P202294PHK to AB), (PRIN 2022 2022NBKCWP to FB), (PRIN 2022 7KTSAT to GDN))

Dutch Research Council (NWO) in the framework of the ENW PPP Fund for the top sectors ((project Proteoform-resolved pharmacokinetics of biopharmaceuticals, no. 019.012), (project Proteoform-resolved pharmacokinetics of biopharmaceuticals, no. 019.012))

Nanokos ((European Commission Ref EUROPEAID/173691/DD/ACT/XK to GDN, GB), (European Commission Ref EUROPEAID/173691/DD/ACT/XK to GDN, GB))

Fondazione Cariplo ((1560-2019 to FB))

Fondazione Roche ((2022 to FB))

Ricerca Finalizzata, Ministry of Health ((RF-2019-12370896 to GDN))

PNRR Missione 4 ((Progetto CN3 - National Center for Gene Therapy and Drugs based on RNA Technology to GDN))

PNRR Missione 6 ((PNRR-MAD-2022-12375913 to GDN))

CARDINNOV, Ministry of Research and University under the umbrella of the Partnership Fostering a European Research Area for Health ((GA N° 101095426 of the EU Horizon Europe Research and Innovation Programme to GDN))

Text and Data Mining valid from 2024-11-30

Version of Record valid from 2024-11-30